SCHEMBL5952948

SCHEMBL5952948

Cc1ccc(-c2nc(C)no2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.71
NPC1 O15118 7/20 0.61
RAB9A P51151 6/20 0.61
NFKB1 P19838 4/20 0.61
NFKB2 Q00653 4/20 0.61
RELA Q04206 4/20 0.61
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
NR1H4 Q96RI1 1/20 0.59
LMNA P02545 1/20 0.57
THRB P10828 1/20 0.57
SMN1; SMN2 Q16637 5/20 0.56
MAPT P10636 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
TP53 P04637 4/20 0.53
PKM P14618 1/20 0.53
ALDH1A1 P00352 1/20 0.53
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
L3MBTL1 Q9Y468 4/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13415305 0.93 ACHE (0.80) ACHENPC1RAB9ANFKB1NFKB2
SCHEMBL3858388 0.85 ACHE (0.69) ACHENPC1RAB9ANFKB1NFKB2
SCHEMBL2645654 0.83 ACHE (0.67) ACHENPC1RAB9ANFKB1NFKB2
SCHEMBL12297019 0.83 ACHE (0.67) ACHENPC1RAB9ANFKB1NFKB2
SCHEMBL400963 0.83 ACHE (0.67) ACHENPC1RAB9ANFKB1NFKB2
SCHEMBL4668357 0.83 ACHE (0.67) ACHENPC1RAB9ANFKB1NFKB2
SCHEMBL981283 0.83 ACHE (1.00) ACHENPC1RAB9ANFKB1NFKB2
SCHEMBL2310534 0.83 ACHE (0.67) ACHENPC1RAB9ANFKB1NFKB2
SCHEMBL806849 0.83 ACHE (0.66) ACHENPC1RAB9ANFKB1NFKB2
SCHEMBL12267148 0.83 NPC1 (0.85) NPC1RAB9ANFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11273168-B2 Methods of treating anxiety by administering a substituted quinolone OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-03-15 US disclosed
US-20210347772-A1 AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-11-11 US disclosed
EP-3394056-B1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2021-04-14 EP disclosed
US-10870657-B2 Compounds for the treatment of cancer and inflammatory disease SHY Therapeutics LLC (US) 2020-12-22 US disclosed
US-10703757-B2 Compounds and methods for CDK8 modulation and indications therefor PLEXXIKON INC. (US) 2020-07-07 US disclosed
US-20190218229-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE SHY Therapeutics LLC 2019-07-18 US disclosed
US-20180215763-A1 COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. 2018-08-02 US disclosed
WO-2018118781-A1 FUNGICIDAL OXADIAZOLES FMC CORPORATION (US) 2018-06-28 WO disclosed
US-20180028660-A1 DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST JANSSEN PHARMACEUTICA NV (BE) 2018-02-01 US disclosed
US-20180028660-A1 DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST JANSSEN PHARMACEUTICA NV (BE) 2018-02-01 US disclosed
US-20080108624-A1 Methylene Dipiperidine Derivatives GLAXO GROUP LIMITED (GB) 2008-05-08 US disclosed
US-20080090027-A1 Composition, retardation plate, and liquid-crystal display device FUJIFILM CORPORATION (JP) 2008-04-17 US disclosed
US-20080075892-A1 Optically-Anisotropic Film and Liquid-Crystal Display Device FUJIFILM CORPORATION (JP) 2008-03-27 US disclosed
US-20080064879-A1 Compound ,Composition And Thin Film FUJIFILM CORPORATION (JP) 2008-03-13 US disclosed
US-7253158-B2 Sulfonamides HOFFMANN-LA ROCHE INC. (US) 2007-08-07 US disclosed
EP-1499600-B1 HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-07-25 EP disclosed
US-20070065601-A1 Optical film, and polarizing plate and liquid crystal display device using the same FUJI PHOTO FILM CO., LTD. (JP) 2007-03-22 US disclosed
US-20070054917-A1 Piperazine derivates and their use for the treatment of neurological and psychiatric diseases GLAXO GROUP LIMITED (GB) 2007-03-08 US disclosed
US-20070054917-A1 Piperazine derivates and their use for the treatment of neurological and psychiatric diseases GLAXO GROUP LIMITED (GB) 2007-03-08 US disclosed
WO-2005051931-A2 PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108624-A1 Methylene Dipiperidine Derivatives DRD2, DRD4, PNMT ACHE 72/4885NPC1 1558/4885RAB9A 2690/4885
US-20070054917-A1 Piperazine derivates and their use for the treatment of neurological and psychiatric diseases GRIN2A, GRIK5, GRIN2C ACHE 125/4885NPC1 485/4885RAB9A 1943/4885
US-11273168-B2 Methods of treating anxiety by administering a substituted quinolone CRH, MC2R, HTR3C ACHE 450/4885NPC1 2037/4885RAB9A 3956/4885
US-10703757-B2 Compounds and methods for CDK8 modulation and indications therefor CDK8, CDK7, CDK18 ACHE 4061/4885NPC1 4559/4885RAB9A 3144/4885
US-20190218229-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE MAPK1, MAPK6, MAP3K1 ACHE 4105/4885NPC1 2556/4885RAB9A 2574/4885
US-10870657-B2 Compounds for the treatment of cancer and inflammatory disease MAPK6, MAP3K6, MAPK4 ACHE 4419/4885NPC1 2024/4885RAB9A 2641/4885
US-20180028660-A1 DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST PPARG, PPARA, DGAT1 ACHE 2410/4885NPC1 342/4885RAB9A 3123/4885
US-20080075892-A1 Optically-Anisotropic Film and Liquid-Crystal Display Device L1CAM, CRY1, TLN1 ACHE 933/4885NPC1 1787/4885RAB9A 247/4885
US-20210347772-A1 AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 LRRK2, PARK7, GDI2 ACHE 704/4885NPC1 1367/4885RAB9A 94/4885
US-20180215763-A1 COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR CDK8, CDK7, CDK18 ACHE 4061/4885NPC1 4559/4885RAB9A 3144/4885
US-20080064879-A1 Compound ,Composition And Thin Film YBX1, H1-2, YBX3 ACHE 4232/4885NPC1 4601/4885RAB9A 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.